Med24
peptide-development 8. 10. 2026 • 2 min read • Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of qualitative methods for the detection of GLP-1 receptor agonists in serum and dried blood spots by LC-HRMS/MS for doping control purposes

The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management has raised concerns about their potential misuse in sports, where effects such as weight loss, glucose-dependent insulin secretion, and enhanced mitochondrial biogenesis may offer performance advantages. Although currently...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management has raised concerns regarding potential misuse in sports, where effects such as weight loss and enhanced mitochondrial biogenesis may offer performance advantages. In response to these concerns, a study developed detection methods for five GLP-1 receptor agonists, alongside the endogenous metabolite GLP-1(9-36)-NH 2, within serum and dried blood spot (DBS) samples using liquid-chromatography and high-resolution tandem mass spectrometry (LC-HRMS/MS). The aim was to support doping control purposes.

Detection Methodologies

For analytes expected to have low blood concentrations – exenatide, lixisenatide, and GLP-1(9-36)-NH 2 – affinity purification utilizing magnetic beads coupled with anti-GLP-1 antibodies and GLP-1 receptor fusion proteins was employed. This technique achieved limits of detection ranging from 9.4 pg/mL (exenatide) to 48 pg/mL (lixisenatide and GLP-1(9-36)-NH 2 ) in 100 μL of serum. Serum analysis demonstrated superior sensitivity compared to DBS, and was therefore prioritized. For higher-abundant, lipidated peptides – liraglutide, semaglutide, and tirzepatide – mixed-mode anion-exchange solid-phase extraction was utilized. This approach yielded LODs ranging from 0.48 ng/mL (tirzepatide) to 4.7 ng/mL (liraglutide and semaglutide) in serum, and 0.95 ng/mL (liraglutide and semaglutide) to 3.8 ng/mL (tirzepatide) in DBS. Both serum and DBS samples proved suitable for reliable detection.

Sponsored content

Validation and Confirmation

Furthermore, the developed methods were validated using post-administration samples from humans treated with semaglutide and tirzepatide, as well as murine samples following administration of exenatide, lixisenatide, and liraglutide, confirming their suitability for sports drug testing.”}

Original Scientific Source
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement